Skip to Content
Morningstar
Get 14 Days Free

Ingredion Inc INGR

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Maintaining $120 FVE as Ingredion Reports Strong Second-Quarter Results; Shares Undervalued

Seth Goldstein, CFA Senior Equity Analyst

Analyst Note

| Seth Goldstein, CFA |

Ingredion reported strong second-quarter results as adjusted operating income was up 64% versus the prior-year quarter. The growth was driven by higher volume, increased prices, and a mix shift toward specialty products. Management reinstated guidance for the year and expects 2021 adjusted earnings per share to be in line with 2019. The results were slightly above our view for the year that Ingredion would see sales continue to recover after the COVID-19-related slowdown affected 2020 results. We have slightly increased our near-term outlook for Ingredion. We have also updated our long-term tax forecast for the impact of a higher U.S. corporate tax rate. Having updated our model to reflect these changes, we maintain our $120 fair value estimate. Our narrow moat rating is also unchanged.

Read Full Analysis

Company Profile

Business Description

Ingredion manufactures ingredients for the food, beverage, paper, and personal-care industries. Sweeteners (syrups, maltodextrins, dextrose, and polyols) account for about 35% of sales, starches (for food and industrial use) around 45%, and co-products the balance. Value-added, specialty ingredients account for nearly one third of sales, with the balance being commodity-grade ingredients. With the majority of sales outside the U.S., Ingredion is a global player with good exposure to developing markets, including Latin America and Asia-Pacific.

Contact
5 Westbrook Corporate Center
Westchester, IL, 60154
T +1 708 551-2600
Sector Consumer Defensive
Industry Packaged Foods
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2020
Stock Type Slow Growth
Employees 12,000

Related

Our Picks
19 Elite Small-Caps on Sale
These wide- and narrow-moat small companies are undervalued according to our metrics.
Susan Dziubinski
Our Picks
14 Undervalued Small-Cap Stocks
These stocks all have narrow or wide economic moats and are undervalued by our metrics.
Susan Dziubinski
Our Picks
33 Undervalued Stocks
Here are our analysts' top ideas in each sector this quarter.
Susan Dziubinski
Quarter-End Insights
Pockets of Value Remain in Agriculture, Chemicals Industries
Decline in the demand for lithium should be short-lived.
Kristoffer Inton
Stock Strategist
6 More Stocks We Like
After reviewing our fair value estimates, we think these names are oversold.
Susan Dziubinski
Our Picks
Defensive Stocks on Sale
These high-quality names are trading at 5-star levels.
Susan Dziubinski
Stock Strategist Industry Reports
Long-Term Opportunities in Agriculture Stocks
Fewer acres planted will likely result in lower crop input volumes, but we expect profit impacts to be short-lived.
Seth Goldstein
US Videos
We’re Excited About Undervalued Ingredion
The narrow-moat food ingredient firm should be able to grow profitably over the long term.
Seth Goldstein
Stock Strategist
Ingredion Benefits From Improving Product Mix
As specialty ingredients make up more of the portfolio, we expect rising profits.
Seth Goldstein
Stock Strategist
Ingredion Has the Recipe for Growth
It should benefit from health trends, demographics, and changing consumer preferences.
Adam Kindreich, CFA
Fund Spy
Good Funds With Commodity Exposure
Commodities are a big part of these funds' portfolios, for better and for worse.
David Kathman
Investing Specialists
Commodities: Whether, What, and How Much?
Readers weigh in on whether this asset class is 'must have' or 'must avoid.'
Christine Benz
Premium Article
Tocqueville Small Cap Value Gets Its Ideas from Home
Food,furniture companies among its recent acquisitions.
Hap Bryant

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.